In contrast to HNSCC, EGFR TKIs induce significant tumor regression in NSCLC patients, but only in patients that harbor somatic mutations in exons of EGFR that code for the tyrosine kinase domain (~15-35% of NSCLC patients) [8, 9]. This evidence concerns the gene EGFR and neoplasm.